NASDAQ · Biotechnology

CDXS (CDXS) Stock

$1.47 -2.00% NASDAQ: CDXS Healthcare

Valuation

MetricValue
Price$1.47
Market Cap$133.62M
P/E Ratio-5.06
P/B Ratio4.51
P/S Ratio2.94
EPS (TTM)$0.00
52-Week High$3.87
52-Week Low$0.96
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-86.27%
ROA-29.73%
ROCE-74.51%
Gross Margin-55.71%
Operating Margin-54.29%
Net Margin-40.96%
Debt/Equity1.69
Current Ratio3.88

Annual Financials (USD)

Metric20212022202320242025
Revenue$105.0M$139.0M$70.0M$59.0M$70.0M
Operating Profit$-23.0M$-35.0M$-68.0M$-59.0M$-38.0M
Net Profit$-21.0M$-34.0M$-76.0M$-65.0M$-44.0M
EPS$-0.33$-0.51$-1.12$-0.89$-0.50
Op Margin-21.7%-25.2%-97.0%-98.6%-54.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$246.0M$250.0M$137.0M$149.0M$148.0M
Total Liabilities$82.0M$106.0M$50.0M$82.0M$97.0M
Cash$117.0M$114.0M$65.0M$19.0M$51.0M
Borrowings$48.0M$44.0M$16.0M$60.0M$73.0M

Latest News

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA GlobeNewswire · May 20, 2026 Spotlight On Promising Penny Stocks For May 2026 Simply Wall St. · May 11, 2026 Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58 Simply Wall St. · May 11, 2026 Codexis (CDXS) Q1 2026 Earnings Transcript Motley Fool · May 8, 2026 Codexis, Inc. Q1 2026 Earnings Call Summary Moby · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$11.0M$-53.0M$-49.0M$-19.0M
Investing Cash Flow$-35.0M$-22.0M$-9.0M$-61.0M$19.0M
Financing Cash Flow$-1.0M$-1.0M$0$0$0
Net Cash Flow$-32.0M$-3.0M$-49.0M$-46.0M$32.0M
Free Cash Flow$-28.0M$3.0M$-57.0M$-54.0M$-24.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-9.62%
Quick Ratio5.23
Interest Coverage-7.60
Return 1Y-30.62%
Return 3Y-32.17%
Return 5Y-89.16%

Ownership

Insiders Held7.41%
Institutions Held74.95%
Institutions Float Held80.95%
Institutional HolderSharesReport Date
Aberdeen Group plc8,680,3682026-03-31
Blackrock Inc.7,028,7732026-03-31
Opaleye Management Inc.6,785,0002026-03-31
Nantahala Capital Management, LLC4,123,6132026-03-31
Millennium Management Llc3,998,1302026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARMPArmata Pharmaceuticals, Inc. $4.64 -0.43% -0.60 $170.34M 0.00%
CCCC $3.52 -0.85% -2.54 $389.20M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%
IMDXInsight Molecular Diagnostics Inc. $4.70 -0.84% -3.13 $151.76M 0.00%
IPHAInnate Pharma S.A. $1.79 +0.14% -2.89 $168.32M 0.00%

About CDXS

CDXS is led by CEO Alison Moore, employs 188 people, headquartered in US, publicly traded since 2010.

CDXS stock trades at $1.47 with a market capitalization of $133.62M. The stock is valued at a price-to-earnings (P/E) ratio of -5.06, price-to-book of 4.51, price-to-sales of 2.94. Over the past 52 weeks the stock has ranged between $0.96 and $3.87, and currently trades 62.0% below its 52-week high.

On profitability, CDXS generates a return on equity (ROE) of -86.27%, return on capital employed of -74.51%, an operating margin of -54.29%, a net profit margin of -40.96%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides